About Acrivon Therapeutics, Inc.

Acrivon is a clinical stage biopharmaceutical company discovering and developing precision oncology medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company’s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. The company also has a preclinical cell cycle program with an undisclosed target.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

Position Overview:

The Histology Lab Manager will be a key member of Acrivon Therapeutics’ Biomarker Development Team and will provide hands-on support in laboratory studies with a focus on biomarker discovery and translational research in the oncology area. Working independently and collaboratively as a member of a cross functional team, the candidate will have ample opportunity to grow and contribute to the understanding of mechanisms of action/resistance to drugs. The candidate will actively participate in characterizing and evaluating predictive and pharmacodynamic biomarkers for patient selection identified using Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.
The candidate will alsosupport
Acrivon’s
CLIA laboratory with FFPE sectioning and staining.

This position reports to the VP, Biomarker Development and will be located at our US headquarters in Watertown, MA.

.

Duties and Responsibilities:

• Perform microtome sectioning of FFPE tissue specimens, H&E and special stains.

• Provide FFPE sectioning, H&E and special stains services to
  Acrivon’s CLIA laboratory, with additional
  training if needed.

• Perform immunohistochemistry staining when needed.

• Organize and handle animal tissue specimens for tissue FFPE processing, embedding, sectioning, and staining.
  

• Organize and handle extensive collection of human FFPE tissue samples

• Prepare and section TMAs (with additional training if needed).

• Maintain accurate inventory for tissue and slide specimens.

• Ensure proper maintenance of
  histology lab equipment.

• Comply with established laboratory policies for universal precautions and safety.

Requirements and Qualifications

• Extensive experience working in histology laboratory, excellent microtome skills, experience with H&E and special stains.

• Extensive experience with immunohistochemistry is preferred.

• Undergraduate/associate degree in biology, related science or equivalent with at least 4-5 years of relevant experience in hospital, academic or industry setting.

• Preferably completion of an accredited histotechnology program.

• Excellent collaboration, communication, and interpersonal skills with the ability to interact effectively with internal and external high achieving team environments.

• Ability to troubleshoot effectively and constructively implement solutions within broader teams.

Acrivon Therapeutics is proud to be an equal opportunity employer and to provide equal opportunities to all employees and applicants for employment without regard to race, color, religion, sex or gender identity, national origin, age, disability, sexual orientation, or genetics. In addition to federal law requirements, Acrivon Therapeutics complies with applicable state and local laws governing nondiscrimination in employment.